Paradigm Biopharmaceuticals Ltd has released a press release.
PAR Receives US Ethics Approval for Phase 3
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- March 2025 Quarterly Activities Report & Appendix 4C
- S&P DJI Announces March 2025 Quarterly Rebalance
- Paradigm Secures Ethics Approval for Phase 3 Trial
- Loyalty and Piggyback Options Program
- PAR Selects Advanced Clinical as CRO for Phase 3
Later from Paradigm Biopharmaceuticals
- Paradigm Strengthens OA Pipeline with Strategic Acquisition
- Paradigm Secures US$27M to Advance Phase 3 OA Trial
- June 2025 Quarterly Activities Report & Appendix 4C
- Appendix 4E and 2025 Annual Report
- Phase 3 Knee OA Trial Recruiting and Dosing in AUS & US
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals